Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069893 | 0.76 | NISCH (0.45) | POLB | |
| SCHEMBL6374553 | 0.76 | NISCH (0.45) | POLB | |
| SCHEMBL442707 | 0.76 | ATM (0.50) | POLBCASP6ATM | |
| SCHEMBL5937077 | 0.75 | — | — | |
| SCHEMBL2884153 | 0.74 | — | — | |
| SCHEMBL5803090 | 0.74 | TSHR (0.35) | — | |
| SCHEMBL4769203 | 0.73 | CA2 (0.31) | — | |
| SCHEMBL3877557 | 0.71 | AOC2 (0.38) | POLB | |
| SCHEMBL7343048 | 0.70 | — | — | |
| SCHEMBL6368347 | 0.70 | HPGD (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486945-B2 | Heterocyclic inhibitors of an Hh-signal cascade, medicinal compositions based thereon and methods for treating diseases caused by the aberrant activity of an Hh-signal system | Ivachtchenko, Alexandre Vasilievich (US) | 2013-07-16 | — | — | US | disclosed |
| US-7148242-B2 | N-formyl hydroxylamine compounds, compositions and methods of use | NOVARTIS AG (CH) | 2006-12-12 | — | — | US | disclosed |
| EP-1401828-B1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARM INC (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1401828-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | Vicuron Pharmaceuticals, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | VICURON HOLDINGS LLC | 2003-03-06 | — | — | US | disclosed |
| WO-2002102790-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARMACEUTICALS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | PDF, HNMT, AADAC | POLB 249/4885CASP6 2417/4885ATM 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.